A theoretical model for prescription of the patient-specific therapeutic activity therapy of Graves' disease

被引:28
作者
Di Martino, F
Traino, AC
Brill, AB
Stabin, MG
Lazzeri, M
机构
[1] Osped S Chiara, Serv Fis Sanitaria, I-56125 Pisa, Italy
[2] Vanderbilt Univ, Dept Radiol & Radiol Sci, Nashville, TN 37232 USA
关键词
D O I
10.1088/0031-9155/47/9/305
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
A fundamental function of the thyroid is to extract iodine from the blood, synthesize it into thyroid hormones, and release it into the circulation under feedback control by pituitary-secreted hormones. This capability of the thyroid, termed as functionality, can in principle be related to the severity of hyperthyroidism in individual patients. In this paper the uptake and release of I-131 by the thyroid following the administration of I-131 therapy for Graves' disease has been theoretically studied. The kinetics of iodine in the thyroid and blood have been evaluated using a two-compartment model. This simplified model appears to be adequate for dosimetry purposes and allows one to correlate levels of increased thyroid functionality (hyperthyroidism) with clinically measurable kinetic parameters. An expression has been derived for the rate of change of thyroid mass following therapy; this has the same form as an empirical relationship described in an earlier work. A method is presented for calculation of the amount of radioiodine activity to be administered to individual patients in order to achieve the desired final functionality of the gland. The activity to be administered is based on measurements of I-131 kinetics after the administration of a 'low-activity' (1850 kBq) tracer for treatment planning.
引用
收藏
页码:1493 / 1499
页数:7
相关论文
共 12 条
  • [1] Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: Is more than seven-thousand rad target dose necessary?
    Bajnok, L
    Mezosi, E
    Nagy, E
    Szabo, J
    Sztojka, I
    Varga, J
    Galuska, L
    Leovey, A
    [J]. THYROID, 1999, 9 (09) : 865 - 869
  • [2] BOCKISCH A, 1993, J NUCL MED, V34, P1632
  • [3] Di Martino F, 2000, PHYS MEDICA, V16, P127
  • [4] *ICRP, 1997, 78 ICRP
  • [5] NORDYKE RA, 1991, J NUCL MED, V32, P411
  • [6] RADIOIODINE THERAPY OF GRAVES HYPERTHYROIDISM - STANDARD VS CALCULATED (131)IODINE ACTIVITY - RESULTS FROM A PROSPECTIVE, RANDOMIZED, MULTICENTER STUDY
    PETERS, H
    FISCHER, C
    BOGNER, U
    REINERS, C
    SCHLEUSENER, H
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1995, 25 (03) : 186 - 193
  • [7] Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism: Results of a prospective, randomized, multicentre study
    Peters, H
    Fischer, C
    Bogner, U
    Reiners, C
    Schleusener, H
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1996, 26 (01) : 59 - 63
  • [8] Siegel JA, 1999, J NUCL MED, V40, p37S
  • [9] Influence of thyroid volume reduction on calculated dose in radioiodine therapy of Graves' hyperthyroidism
    Traino, AC
    Di Martino, F
    Lazzeri, M
    Stabin, MG
    [J]. PHYSICS IN MEDICINE AND BIOLOGY, 2000, 45 (01) : 121 - 129
  • [10] Study of the correlation between administered activity and radiation committed dose to the thyroid in 131I therapy of Graves' disease
    Traino, AC
    Di Martino, F
    Lazzeri, M
    Stabin, MG
    [J]. RADIATION PROTECTION DOSIMETRY, 2001, 95 (02) : 117 - 124